Skip to main content

Table 2 The effect of RES and SLN-RES treatment on the body weight gain, fasting blood sugar, insulin, and HOMA index in diabetic rat models

From: Oral Administration of Resveratrol-Loaded Solid Lipid Nanoparticle Improves Insulin Resistance Through Targeting Expression of SNARE Proteins in Adipose and Muscle Tissue in Rats with Type 2 Diabetes

Group DC DC + RES DC + SLN-RES
Body weight (g) − 69.4 ± 14.4 − 49.9 ± 18.0α+ − 12.3 ± 2.8α#π
FBS (mg/dl) + 211.3 ± 92.1 + 98.3 ± 38.6α* + 38.5 ± 13.6α#δ
Insulin (μU/ml) − 4.0 ± 1.2 − 1.8 ± 0.9α#π − 0.9 ± 0.2α#π
HOMA + 3.0 ± 1.1 + 2.2 ± 0.8α# + 0.1 ± 0.04α#πδ
  1. The alteration of parameters was expressed as compared with healthy control group. DC diabetic control, RES resveratrol treatment 10 mg/kg, SLN-RES resveratrol-loaded solid lipid nanoparticles containing 10 mg/kg of resveratrol, FBS fasting blood sugar, HOMA homeostasis model assessment-estimated insulin resistance. Data were expressed as mean ± SD
  2. αCompared to the DC group
  3. δThere was a significant difference between RES and SLN-RES group (p < 0.05)
  4. πRestored to the HC group (there was no significant difference compared to the HC group (p > 0.05)).
  5. *p < 0.05
  6. +p < 0.01
  7. #p < 0.001